155 related articles for article (PubMed ID: 37931892)
1. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
3. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.
Hidalgo-Tenorio C; Sadyrbaeva-Dolgova S; Enríquez-Gómez A; Muñoz P; Plata-Ciezar A; Miró JM; Alarcón A; Martínez-Marcos FJ; Loeches B; Escrihuela-Vidal F; Vinuesa D; Herrero C; Boix-Palop L; Del Mar Arenas M; Vázquez EG; de Las Revillas FA; Pasquau J;
Int J Antimicrob Agents; 2023 Sep; 62(3):106918. PubMed ID: 37442488
[TBL] [Abstract][Full Text] [Related]
4. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
[TBL] [Abstract][Full Text] [Related]
8. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin for infective endocarditis: a single centre experience.
Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.
Brandariz-Núñez D; Luances-Rodríguez A; Feijoo-Vilanova P; Gutiérrez-Urbón JM; Ramudo-Cela L; Martín-Herranz MI; Margusino-Framiñán L
Rev Esp Quimioter; 2024 Aug; 37(4):334-340. PubMed ID: 38881525
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
[TBL] [Abstract][Full Text] [Related]
12. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Gonzalez J; Andrade DC; Niu J
Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin in clinical practice: a particular place for the elderly?
Wackenheim C; Le Maréchal M; Pluchart H; Gavazzi G; Blanc M; Caspar Y; Pavese P;
Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):977-979. PubMed ID: 35471751
[TBL] [Abstract][Full Text] [Related]
14. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
Pascale R; Maccaro A; Mikus E; Baldassarre M; Tazza B; Esposito F; Rinaldi M; Tenti E; Ambretti S; Albertini A; Viale P; Giannella M; Bartoletti M
J Glob Antimicrob Resist; 2022 Sep; 30():390-394. PubMed ID: 35878780
[TBL] [Abstract][Full Text] [Related]
15. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin in Gram-positive periprosthetic joint infections.
Simon S; Frank BJH; Hartmann S; Hinterhuber L; Reitsamer M; Aichmair A; Dominkus M; Söderquist B; Hofstaetter JG
J Antimicrob Chemother; 2022 Jul; 77(8):2274-2277. PubMed ID: 35678452
[TBL] [Abstract][Full Text] [Related]
18. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
Evins C; Lancaster H; Schnee AE
Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.
Tobudic S; Forstner C; Burgmann H; Lagler H; Ramharter M; Steininger C; Vossen MG; Winkler S; Thalhammer F
Clin Infect Dis; 2018 Aug; 67(5):795-798. PubMed ID: 29659732
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]